ABOUT GENSCO® PHARMA
Gensco® Pharma is a specialty pharmaceutical company focusing on research, development and marketing of transdermal prescription products. As an innovator of pharmaceutical products, Gensco® Pharma currently manufactures non-narcotic transdermal analgesic gels utilizing our patented drug delivery solutions. Gensco® Pharma’s airless, closed-system, metered dose technology, MDose™, dispenses the exact amount of medication per application, yielding maximized results and minimized side effects. As a healthcare partner, Gensco® is in continual pursuit of novel and effective therapies designed to improve health.
Gensco® Pharma: healthcare visionaries, boundless…
Gensco® Pharma is committed to Better Science for Health.
Our resources are focused on innovative research, the development of superior quality medications and unique delivery systems. We are an evidence-based solutions company that is progressively developing products utilizing new technologies that deliver outcomes to reduce the effects caused by disease or pathology.
WORKING WITH GENSCO®
Gensco® works with nationally recognized suppliers. We are a rapidly growing branded pharmaceutical manufacturer that extends resources including education and training along with customized marketing programs to help grow our distributor partner business. Internally, Gensco® team members provide an array of support services to enable the supply chain seamless delivery and to ensure desired market penetration for our partners.
- Gensco® Pharma Partners with IntelGenx to Market RIZAPORT® in the United States December 12, 2018 Featured, Industry, Press Release, Product Update - Miami, Florida, December 12, 2018 – Gensco® Pharma, a leading specialty pharmaceutical manufacturer specializing in more...
- AAP Issues Flu Vaccine Recommendations for 2018-2019 September 6, 2018 Articles, Industry - All children should receive the flu shot as soon as it is available: AAP [To more...
- A Case Study of Treatment of Recalcitrant Nonpressure Chronic Ulcers Using Astero Gel Topical Hydrogel with 4% Lidocaine for Autolytic Debridement and Pain Management November 13, 2017 Articles, Clinical, Featured, Research -
- An Exploratory, Single-blind Study to Evaluate Both the Onset of Anesthesia of LiDORx® in Patients Aged 18–88 Years November 9, 2017 Clinical, Research -